<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>16</Volume>
				<Issue>8</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>08</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>3241</FirstPage>
			<LastPage>3245</LastPage>
			<ELocationID EIdType="pii">30904</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>Purpose: To examine the effectiveness of mitomycin-C and chemo-hyperthermia in combination for patientswith high-risk non-muscle-invasive bladder cancer. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: Between November 2011-September2013, 43 patients with high-risk non-muscle-invasive bladder cancer undergoing adjuvant chemo-hyperthermiain two centers were evaluated retrospectively. Treatment consisted of 6 weekly sessions, followed by 6 sessions.Recurrence and progression rate, recurrence-free interval and side effects were examined. Analyzed factorsincluded age, gender, smoking status, AB0 blood group, body mass index, T stage and grade, concominant CISassets. The associations between predictors and recurrence were assessed using multivariate Cox proportionalhazard analyses. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: A total of 40 patients completed induction therapy. Thirteen (32.5%) were diagnosedwith tumor recurrence. Median follow-up was 30 months (range 9-39). Median recurrence-free survival was23 months (range 6-36). The Kaplan-Meier-estimated recurrence-free rates for the entire group at 12 and 24months were 82% and 61%. There was no statistically significant difference between patient subgroups. Coxhazard analyses showed that an A blood type (OR=6.23, p=0.031) was an independent predictor of recurrencefree.Adverse effects were seen in 53% of patients and these were frequently grades 1 and 2. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;:Intravesical therapy with combination of mitomycin-C and chemohyperthermia seems to be appropriate inhigh-risk patients with non-muscle-invasive bladder cancer who cannot tolerate or have contraindications forstandard BCG therapy.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Chemohyperthermia</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Recurrence</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Mitomycin C</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Thermochemotherapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">non muscle-invasive bladder cancer</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_30904_2d46daf6610ff5ed69af48e6cb01e4df.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
